Aldeyra The (ALDX) - Total Liabilities
Based on the latest financial reports, Aldeyra The (ALDX) has total liabilities worth $9.66 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Aldeyra The's assets to evaluate the company's liquid asset resilience ratio.
Aldeyra The - Total Liabilities Trend (2011–2025)
This chart illustrates how Aldeyra The's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Aldeyra The.
Aldeyra The Competitors by Total Liabilities
The table below lists competitors of Aldeyra The ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chegg Inc
NYSE:CHGG
|
USA | $122.96 Million |
|
Agabang&Company
KQ:013990
|
Korea | ₩55.55 Billion |
|
U&I Corporation
KQ:056090
|
Korea | ₩31.20 Billion |
|
Tonymoly Co Ltd
KO:214420
|
Korea | ₩106.53 Billion |
|
Mitchell Services Ltd
AU:MSV
|
Australia | AU$50.24 Million |
|
Nexstim Oyj
HE:NXTMH
|
Finland | €9.17 Million |
|
American Lithium Corp
V:LI
|
Canada | CA$1.74 Million |
|
Sterling Tools Limited
NSE:STERTOOLS
|
India | Rs3.01 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Aldeyra The's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ALDX equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aldeyra The's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aldeyra The (2011–2025)
The table below shows the annual total liabilities of Aldeyra The from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $27.81 Million | -17.24% |
| 2024-12-31 | $33.60 Million | +17.77% |
| 2023-12-31 | $28.53 Million | -5.78% |
| 2022-12-31 | $30.28 Million | +10.52% |
| 2021-12-31 | $27.40 Million | +14.92% |
| 2020-12-31 | $23.84 Million | -13.09% |
| 2019-12-31 | $27.44 Million | +223.80% |
| 2018-12-31 | $8.47 Million | +85.25% |
| 2017-12-31 | $4.57 Million | +29.29% |
| 2016-12-31 | $3.54 Million | +6.36% |
| 2015-12-31 | $3.33 Million | +32.90% |
| 2014-12-31 | $2.50 Million | +17.60% |
| 2013-12-31 | $2.13 Million | -92.16% |
| 2012-12-31 | $27.13 Million | +946.16% |
| 2011-12-31 | $2.59 Million | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more